

ACT Onco[®] + Report

PATIENT		
Name: 陳嬌		Patient ID: 48534981
Date of Birth: May 07, 1941		Gender: Female
Diagnosis: Pancreatic cancer		
ORDERING PHYSICIAN		
Name: 姜乃榕醫師		Tel: 886-228712121
Facility: 臺北榮總		
Address: 臺北市北投區石牌路二段 201 號		
SPECIMEN		
Specimen ID: S11170683A	Collection site: Pancreas	Type: FFPE tissue
Date received: Jun 17, 2022	Lab ID: AA-22-03241	D/ID: NA

ABOUT ACT Onco[®]+

The test is a next-generation sequencing (NGS)-based assay developed for efficient and comprehensive genomic profiling of cancers. This test interrogates coding regions of 440 genes associated with cancer treatment, prognosis and diagnosis. Genetic mutations detected by this test include small-scale mutations like single nucleotide variants (SNVs), small insertions and deletions (InDels) (≤ 15 nucleotides) and large-scale genomic alterations like copy number alterations (CNAs). The test also includes an RNA test, detecting fusion transcripts of 13 genes.

SUMMARY FOR ACTIONABLE VARIANTS

VARIANTS/BIOMARKERS WITH EVIDENCE OF CLINICAL SIGNIFICANCE

Genomic Alterations/Biomarkers	Probable Effects in Patient's Cancer Type		Probable Sensitive in Other Cancer Types
	Sensitive	Resistant	
Not detected			

VARIANTS/BIOMARKERS WITH POTENTIAL CLINICAL SIGNIFICANCE

Genomic Alterations/Biomarkers	Possibly Sensitive	Possibly Resistant
CDKN2A Homozygous deletion	Abemaciclib, Palbociclib, Ribociclib	-
KRAS G12R	-	Afatinib, Dacomitinib, Erlotinib, Gefitinib, Osimertinib, Cetuximab, Panitumumab

Note:

- The above summary tables present genomic variants and biomarkers based on the three-tiered approach proposed by US FDA for reporting tumor profiling NGS testing. "Variants/biomarkers with evidence of clinical significance" refers to mutations that are widely recognized as standard-of-care biomarkers (FDA level 2/AMP tier 1). "Variants/biomarkers with potential clinical significance" refers to mutations that are not included in the standard of care but are informational for clinicians, which are commonly biomarkers used as inclusion criteria for clinical trials (FDA level 3/AMP tier 2).
- The therapeutic agents and possible effects to a given drug are based on mapping the variants/biomarkers with ACT Genomics clinical knowledge database. The mapping results only provide information for reference, but not medical recommendation.
- Please refer to corresponding sections for more detailed information about genomic alteration and clinical relevance listed above.

ACTOnco® + Report

TESTING RESULTS

VARIANT(S) WITH CLINICAL RELEVANCE

- Single Nucleotide and Small InDel Variants

Gene	Amino Acid Change	Allele Frequency
KRAS	G12R	46.9%
TP53	S127F	34.3%

- Copy Number Alterations

Chromosome	Gene	Variation	Copy Number
Chr9	CDKN2A	Homozygous deletion	0
Chr1	ARID1A	Heterozygous deletion	1
Chr15	RAD51	Heterozygous deletion	1
Chr16	TSC2	Heterozygous deletion	1
Chr17	TP53	Heterozygous deletion	1
Chr18	SMAD4	Heterozygous deletion	1
Chr9	TSC1	Heterozygous deletion	1
Chr18	TYMS	Amplification	7*

* Increased gene copy number was observed.

- Fusions

Fusion Gene & Exon	Transcript ID
No fusion gene detected in this sample	

- Immune Checkpoint Inhibitor (ICI) Related Biomarkers

Biomarker	Results
Tumor Mutational Burden (TMB)	< 1 muts/Mb
Microsatellite Instability (MSI)	Microsatellite stable (MSS)

Note:

- Variant(s) enlisted in the SNV table may currently exhibit no relevance to treatment response prediction. Please refer to INTERPRETATION for more biological information and/or potential clinical impacts of the variants.
- Loss of heterozygosity (LOH) information was used to infer tumor cellularity. Copy number alteration in the tumor was determined based on 41% tumor purity.
- For more therapeutic agents which are possibly respond to heterozygous deletion of genes listed above, please refer to APPENDIX for more information.
- TMB was calculated by using the sequenced regions of ACTOnco®+ to estimate the number of somatic nonsynonymous mutations per megabase of all protein-coding genes (whole exome). The threshold for high mutation load is set at ≥ 7.5 mutations per megabase. TMB, microsatellite status and gene copy number deletion cannot be determined if calculated tumor purity is < 30%.

ACT Onco[®] + Report

THERAPEUTIC IMPLICATIONS TARGETED THERAPIES

Genomic Alterations	Therapies	Effect
Level 3A		
KRAS G12R	Afatinib, Dacomitinib, Erlotinib, Gefitinib, Osimertinib, Cetuximab, Panitumumab	resistant
Level 3B		
CDKN2A Homozygous deletion	Abemaciclib, Palbociclib, Ribociclib	sensitive

Therapies associated with benefit or lack of benefit are based on biomarkers detected in this tumor and published evidence in professional guidelines or peer-reviewed journals.

Level	Description
1	FDA-recognized biomarkers predictive of response or resistance to FDA approved drugs in this indication
2	Standard care biomarkers (recommended by the NCCN guideline) predictive of response or resistance to FDA approved drugs in this indication
3A	Biomarkers predictive of response or resistance to therapies approved by the FDA or NCCN guideline in a different cancer type
3B	Biomarkers that serve as inclusion criteria for clinical trials (minimal supportive data required)
4	Biomarkers that show plausible therapeutic significance based on small studies, few case reports, or preclinical studies

ACT Onco[®] + Report

IMMUNE CHECKPOINT INHIBITORS (ICIs)

No genomic alterations detected to confer sensitivity or lack of benefit to immune checkpoint therapies.

- Other Biomarkers with Potential Clinical Effects for ICIs

Genomic Alterations	Potential Clinical Effects
Not detected	

Note: Tumor non-genomic factors, such as patient germline genetics, PDL1 expression, tumor microenvironment, epigenetic alterations or other factors not provided by this test may affect ICI response.

CHEMOTHERAPIES

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to chemotherapies.

HORMONAL THERAPIES

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to hormonal therapies.

OTHERS

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to other therapies.

Note:

Therapeutic implications provided in the test are based solely on the panel of 440 genes sequenced. Therefore, alterations in genes not covered in this panel, epigenetic and post-transcriptional and post-translational factors may also determine a patient's response to therapies. In addition, several other patient-associated clinical factors, including but not limited to, prior lines of therapies received, dosage and combinations with other therapeutic agents, patient's cancer types, sub-types, and/or stages, may also determine the patient's clinical response to therapies.

ACT Onco[®] + Report

VARIANT INTERPRETATION

KRAS G12R

Biological Impact

The V-Ki-Ras2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog (KRAS) gene encodes a small GTPase protein, a member of the RAS family of small GTPases, which catalyze the hydrolysis of GTP to GDP. RAS proteins cycle between an active (GTP-bound) and an inactive (GDP-bound) state, to activate the downstream oncogenic pathways, including the PI3K/AKT/mTOR and MAPK pathways^[1]. KRAS mutations occur primarily in three hotspots G12, G13 and Q61, and less frequently in codon A146^{[1][2]}. These are activating mutations that lead to constitutive activation and persistent stimulation of the downstream signaling pathways^{[3][4]}. Mutations in KRAS have been reported in a diverse spectrum of human malignancies, including pancreatic carcinomas (>80%)^{[1][5]}, colon carcinomas (40-50%)^{[6][7]}, and lung carcinomas (30-50%)^{[8][9]}, but are also present in biliary tract malignancies, endometrial cancer, cervical cancer, bladder cancer, liver cancer, myeloid leukemia and breast cancer^[2].

KRAS G12R is a hotspot mutation that lies within a GTP binding region of the KRAS protein (UniProtKB). G12R results in decreased KRAS GTPase activity and increased activation of downstream signaling in vitro^{[10][11]}.

Therapeutic and prognostic relevance

Except for KRAS G12C, other KRAS mutants are not currently targetable, but the downstream MEK serves as a potential target^[12]. MEK inhibitors trametinib, cobimetinib, and binimetinib were approved by the U.S. FDA for patients with advanced metastatic melanoma whose tumors harbor BRAF V600 mutations^{[13][14][15][16]}.

There are case reports indicated that patients harboring a KRAS mutation may benefit from MEK inhibitor treatment. A patient with small cell neuroendocrine carcinoma (SCNEC) of the cervix harboring a KRAS G12D mutation showed significant response with trametinib^[17]. Another low-grade serous carcinoma case with KRAS G12D also has sustained response to trametinib (Am J Clin Exp Obstet Gynecol 2015;2(3):140-143). In addition, a low-grade serous ovarian cancer patient harboring KRAS G12V mutation showed stable disease after 8 weeks of binimetinib treatment, and demonstrated a partial response after another 26 weeks of treatment^[18]. However, trametinib did not demonstrate superiority to docetaxel in KRAS-mutant non-small cell lung cancer (NSCLC) patients, based on results from a randomized Phase II study^[19].

Both clinical and preclinical studies demonstrated a limited response to monotherapy using MEK inhibitors^[20]. Moreover, several clinical trials are in progress to evaluate the combination of MEK and mTOR inhibition as a new potential therapeutic strategy in CRC^[21], and in patient-derived xenografts of RAS-mutant CRC, inhibition of MEK and mTOR suppressed tumor growth, but not tumor regression^[22]. A study using the CRC patient-derived xenograft (PDX) model showed that the combination of trametinib, a MEK inhibitor, and palbociclib, a CDK4/6 inhibitor, was well tolerated and resulted in objective responses in all KRAS mutant models^[23].

KRAS mutation has been determined as an inclusion criterion for the trials evaluating MEK inhibitors efficacies in various types of solid tumors (NCT03704688, NCT02399943, NCT02285439, NCT03637491, NCT04214418).

Cetuximab and panitumumab are two EGFR-specific antibodies approved by the U.S. FDA for patients with KRAS wild-type metastatic colorectal cancer (NCT00154102, NCT00079066, NCT01412957, NCT00364013). Results from the PRIME and FIRE-3 trials indicated that panitumumab and cetuximab did not benefit patients with KRAS or NRAS mutations and may even have a detrimental effect in these patients^[24]. Taken together, the National Comprehensive Cancer Network (NCCN) recommended that, cetuximab and panitumumab should only be used if both KRAS and NRAS genes are normal (NCCN guidelines)^{[25][26]}. Numerous studies have demonstrated the presence of KRAS or NRAS mutations at exon 2, 3 or 4 as a predictor of resistance to anti-EGFR therapies^{[27][28][29][30][31][32][33]}.

ACT Onco[®] + Report

Sorafenib, a multi-kinase inhibitor, has been shown to be beneficial in KRAS-mutant CRC^[34], KRAS-mutant NSCLC^[35], and KRAS-amplified melanoma^[36].

There has been conflicting data on the effect of KRAS mutation on the efficacy of bevacizumab in metastatic CRC patients (J Clin Oncol 34, 2016 (suppl; abstr 3525))^{[37][38]}.

In NCCN guidelines for NSCLC, KRAS mutations have been suggested as an emerging biomarker for EGFR TKIs in NSCLC patients. KRAS mutations are associated with a lack of efficacy of EGFR TKIs, including erlotinib, gefitinib, afatinib, and osimertinib, in NSCLC patients^{[39][40][41]}.

Studies have shown that KRAS mutation, especially those occurs in exon 2 (codon 12 or 13) and codon 61 indicated a poor prognosis for patients with CRC^[42].

In low-grade serous carcinoma of the ovary or peritoneum, patients with KRAS or BRAF mutations (n=21) had a significantly better OS than those with wild-type KRAS or BRAF (n=58) (106.7 months vs 66.8 months), respectively^[43]. In ovarian serous borderline tumor with recurrent low-grade serous carcinoma, patient harboring KRAS G12V mutation appeared to have shorter survival time^[44].

In 242 patients with unresectable pancreatic cancer, the presence of KRAS G12R (N=17) or G12D (N=92) was associated with poorer prognosis (overall survival HR 1.6; 95% confidence interval 1.11-2.28)^[45].

In a Phase II trial, a patient with Erdheim-Chester disease harboring KRAS G12R and ARAF P216A achieved a complete response to cobimetinib treatment^[46]. An exploratory study demonstrated that pancreatic cancer patients with KRAS G12R mutation had better response to the combination of gemcitabine and cobimetinib than patients with KRAS G12D and G12V. One of six patients with KRAS G12R had partial response and five had stable disease and median PFS was 6 months^[47].

TP53 S127F, Heterozygous deletion

Biological Impact

TP53 encodes the p53 protein, a crucial tumor suppressor that orchestrates essential cellular processes including cell cycle arrest, senescence and apoptosis^[48]. TP53 is a proto-typical haploinsufficient gene, such that loss of a single copy of TP53 can result in tumor formation^[49].

S127F lies within the DNA-binding domain of the p53 protein (UniProtKB). This mutation has been identified in the sequencing studies^{[50][51]}. To date, the biological impact of this mutation on the p53 protein function remains unknown.

Therapeutic and prognostic relevance

Despite having a high mutation rate in cancers, there are currently no approved targeted therapies for TP53 mutations. A phase II trial demonstrated that Wee1 inhibitor (AZD1775) in combination with carboplatin was well tolerated and showed promising anti-tumor activity in TP53-mutated ovarian cancer refractory or resistant (< 3 months) to standard first-line therapy (NCT01164995)^[52].

In a retrospective study (n=19), advanced sarcoma patients with TP53 loss-of-function mutations displayed improved progression-free survival (208 days versus 136 days) relative to patients with wild-type TP53 when treated with pazopanib^[53]. Results from another Phase I trial of advanced solid tumors (n=78) demonstrated that TP53 hotspot mutations are associated with better clinical response to the combination of pazopanib and vorinostat^[54].

Advanced solid tumor and colorectal cancer patients harboring a TP53 mutation have been shown to be more sensitive to bevacizumab when compared with patients harboring wild-type TP53^{[55][56][57]}. In a pilot trial (n=21), TP53-negative

ACT Onco[®] + Report

breast cancer patients demonstrated increased survival following treatment with bevacizumab in combination with chemotherapy agents, Adriamycin (doxorubicin) and Taxotere (docetaxel)^[58]. TP53 mutations were correlated with poor survival of advanced breast cancer patients receiving tamoxifen or primary chemotherapy^{[59][60]}. In a retrospective study of non-small cell lung cancer (NSCLC), TP53 mutations were associated with high expression of VEGF-A, the primary target of bevacizumab, offering a mechanistic explanation for why patients exhibit improved outcomes after bevacizumab treatment when their tumors harbor mutant TP53 versus wild-type TP53^[61].

ARID1A Heterozygous deletion

Biological Impact

The AT-rich interactive domain 1A (ARID1A) gene encodes the BAF250A protein, a component of the SWI/SNF chromatin remodeling complex that plays a role in various cellular functions, including DNA repair, DNA synthesis, and transcription^{[62][63]}. Haploinsufficiency of ARID1A is associated with tumor formation in some cancers^[64]. Inactivation of ARID1A is commonly observed in ovarian, endometrial, uterine, and, gastric cancers^{[65][66][67][68][69]}.

Therapeutic and prognostic relevance

ARID1A is the most frequently mutated genes in ovarian clear cell carcinoma and several synthetic lethality hypothesis-based therapeutic targets in ARID1A mutated cancer are in development. For examples, 1) EZH2 inhibitor^{[70][71]}; 2) AKT-inhibitors MK-2206 and perifosine, as well as PI3K-inhibitor buparlisib^[72]; 3) multiple kinase inhibitor, dasatinib^[73].

Some preclinical evidences suggested that reduced ARID1A expression confers resistance to several HER2/PI3K/mTOR signaling cascade inhibitors such as AZD8055 and trastuzumab, through activation of annexin A1 expression^[74]. Loss or decreased expression of ARID1A has been reported to associate with resistance to platinum-based chemotherapies, shorter overall survival and lower complete response rate in ovarian cancer patients^{[75][76]}.

Low expression of ARID1A is a significant and independent prognostic factor for poor disease-free and overall survival in breast cancer patients^{[77][78]}. Besides, loss of ARID1A expression was more frequently seen in mismatch repair (MMR)-deficient colorectal cancers, predominantly in tumor with MLH1 promoter hypermethylation^[79]. Positive ARID1A expression could independently predict worse overall survival in stage IV CRC patients compared with negative ARID1A expression^[80].

ARID1A mutation has been determined as an inclusion criterion for the trials evaluating olaparib efficacy in metastatic biliary tract cancer (NCT04042831), and niraparib efficacy in melanoma (NCT03925350), pancreatic cancer (NCT03553004), or any malignancy, except prostate cancer (NCT03207347).

The preclinical study discovered that ARID1A deficiency sensitized some tumors to PARP inhibitor drugs, such as olaparib, rucaparib, talazoparib, and veliparib, which block DNA damage repair pathways^[81].

CDKN2A Homozygous deletion

Biological Impact

The Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A) gene encodes the p16 (p16INK4a) and p14 (ARF) proteins. p16INK4a binds to CDK4 and CDK6, inhibiting these CDKs from binding D-type cyclins and phosphorylating the retinoblastoma (RB) protein whereas p14 (ARF) blocks the oncogenic activity of MDM2 by inhibiting MDM2-induced degradation of p53^{[82][83][84]}. CDKN2A has been reported as a haploinsufficient tumor suppressor with one copy loss that may lead to weak protein expression and is insufficient to execute its original physiological functions^[85]. Loss of CDKN2A has been frequently found in human tumors that result in uncontrolled cell proliferation^{[86][87]}.

ACT Onco[®] + Report

Therapeutic and prognostic relevance

Intact p16-Cdk4-Rb axis is known to be associated with sensitivity to cyclin-dependent kinase inhibitors^{[88][89]}. Several case reports also revealed that patients with CDKN2A-deleted tumors respond to the CDK4/6-specific inhibitor treatments^{[90][91][92]}. However, there are clinical studies that demonstrated CDKN2A nuclear expression, CDKN2A/CDKN2B co-deletion, or CDKN2A inactivating mutation was not associated with clinical benefit from CDK4/6 inhibitors, such as palbociclib and ribociclib, in RB-positive patients^{[93][94][95]}. However, CDKN2A loss or mutation has been determined as an inclusion criterion for the trial evaluating CDK4/6 inhibitors efficacy in different types of solid tumors (NCT02693535, NCT02187783).

Notably, the addition of several CDK4/6 inhibitors to hormone therapies, including palbociclib in combination with letrozole, ribociclib plus letrozole, and abemaciclib combines with fulvestrant, have been approved by the U.S. FDA for the treatment of ER+ and HER2- breast cancer^{[89][96][97]}.

In a Phase I trial, a KRAS wild-type squamous non-small cell lung cancer (NSCLC) patient with CDKN2A loss had a partial response when treated with CDK4/6 inhibitor abemaciclib^[91]. Administration of combined palbociclib and MEK inhibitor PD-0325901 yield promising progression-free survival among patients with KRAS mutant non-small cell lung cancer (NSCLC) (AACR 2017, Abstract CT046). Moreover, MEK inhibitor in combination with CDK4/6 inhibitor demonstrates significant anti-KRAS-mutant NSCLC activity and radiosensitizing effect in preclinical models^[98].

A retrospective analysis demonstrated that concurrent deletion of CDKN2A with EGFR mutation in patients with non-small cell lung cancer (NSCLC), predicts worse overall survival after EGFR-TKI treatment^[99].

RAD51 Heterozygous deletion

Biological Impact

The RAD51 gene encodes a recombinase that is crucial for homologous recombination (HR)-mediated repair of double-strand DNA breaks (DSBs) by forming complexes with known tumor suppressors including BRCA1, BRCA2, and PALB2^{[100][101][102]}. RAD51 has been characterized as a haploinsufficient tumor suppressor gene with one copy loss may lead to weak protein expression and is insufficient to execute its original physiological functions^[103]. Overexpression of RAD51 has been observed in many cancer cells, including pancreatic cancer and breast cancer and its hyperexpression is implicated in drug resistance^{[104][105][106][107][108][109][110]}. Germline mutations in RAD51 are associated with increased susceptibility to breast cancer^{[111][112][113][114]}.

Therapeutic and prognostic relevance

RAD51 loss of function mutation has been determined as an inclusion criterion for the trial evaluating olaparib efficacy in ovarian cancer^[115]; rucaparib efficacy in solid tumor (NCT04171700); talazoparib efficacy in lung cancer (NCT03377556); niraparib efficacy in pancreatic cancer (NCT03553004) or any malignancy (except prostate cancer) (NCT03207347).

Preclinical studies showed that decreased RAD51 expression could sensitize cells to olaparib-induced tumor cell cytotoxicity^{[116][117]}.

SMAD4 Heterozygous deletion

Biological Impact

The SMAD family member 4 (SMAD4) gene encodes a transcription factor that acts as a downstream effector in the TGF- β signaling pathway. Upon phosphorylated and activated by serine-threonine receptor kinase, Smad4 is the Co-Smad which recruits other activated R-Smad proteins to the Smad transcriptional complex and regulate TGF- β -targeted genes^[118]. Smad4 has been identified as a haploinsufficient gene with one copy loss may lead to a weak protein expression and is insufficient to execute its original physiological function^[119]. SMAD4 germline mutations are

ACT Onco[®] + Report

associated with juvenile polyposis syndrome (JPS)^{[120][121][122][123]}. Somatic mutations of SMAD4 are commonly observed in pancreatic cancer^[124], colorectal cancer (CRC)^{[122][125][126]}, and less frequently seen in other cancers such as lung adenocarcinoma^[127], head and neck cancer^{[128][129]}, and cutaneous squamous cell carcinoma^[130].

Therapeutic and prognostic relevance

In Chinese patients with metastatic colorectal cancer, SMAD4 or NF1 mutations are suggested as a potential biomarker for poor prognosis to cetuximab-based therapy^[131]. Preclinical data demonstrated that depletion of SMAD4 by shRNA knockdown increased clonogenic survival and cetuximab resistance in HPV-negative head and neck squamous cell carcinoma cells^[132].

SMAD4 is also suggested as a predictive marker for 5-fluorouracil-based chemotherapy in colorectal cancer (CRC)^{[133][134]}. CRC patients with normal SMAD4 diploidy exhibited three-fold higher benefit of 5-FU/mitomycin-based adjuvant therapy when compared with those with SMAD4 deletion^[135].

Results from clinical and meta-analyses showed that loss of SMAD4 in CRC, pancreatic cancer was correlated with poor prognosis^{[136][137][138][139][140][141][142][143]}. In cervical cancer patients, weak cytoplasmic SMAD4 expression and absent nuclear SMAD4 expression were shown to be significantly associated with poor disease-free and overall 5-year survival^[144].

TSC1 Heterozygous deletion

Biological Impact

The tuberous sclerosis complex 1 (TSC1) gene encodes a tumor suppressor, hamartin, a key negative regulator of the mammalian target of rapamycin (mTOR) pathway^{[145][146]}. Mutations in TSC1/TSC2 tumor suppressor genes that result in inactivation of the complex are commonly found in patients with tuberous sclerosis^{[147][148][149]}, while LOH in TSC1/TSC2 has been identified in head and neck squamous cell carcinoma (HNSCC)^[150] and endometrial cancer^[151]. Loss of single TSC1 allele (haploinsufficiency) may provide a growth advantage to bladder epithelial cells, contributing to bladder cancer development^[152]. Both TSC1 and TSC2 mutations cause the autosomal dominant genetic disorder tuberous sclerosis complex (TSC), in which individuals develop a variety of benign but often progressive neoplasms^[153].

Therapeutic and prognostic relevance

Genomic alterations with activating effects of the mTOR signaling pathway (including deletion/inactivation of TSC1/TSC2) have been shown to confer sensitivity to everolimus across multiple neoplasms, such as bladder tumors^[154], gastric, sarcoma, thyroid cancer, and HNSCC^[155]. There were case reports demonstrated the efficacy of sirolimus in malignant uterine perivascular epithelioid cell tumors (PEComa) patients harboring mutations/deletions in TSC1 and TSC2 genes, and temsirolimus in PEComa patients with hyperactivated mTOR pathway. Genomic profiling analysis of GOG248, a Phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer showed that mutations in AKT1, TSC1 and TSC2 may predict clinical benefit from temsirolimus^[156]. Recent studies indicate that there are mTORC1-independent signaling pathways downstream of hamartin-tuberin, which may represent new therapeutic targets^[157].

Everolimus has been approved by the U.S. FDA for Tuberous Sclerosis Complex (TSC)-associated renal angiomyolipoma and Tuberous Sclerosis Complex (TSC)-associated subependymal giant cell astrocytoma (SEGA). This approval is based on the results from EXIST-1, EXIST-2, and Study 2485 trials (NCT00789828, NCT00790400, and NCT00411619).

ACT Onco[®] + Report

TSC2 Heterozygous deletion

Biological Impact

The tuberous sclerosis complex 2 (TSC2) gene encodes a protein called tuberin, which interact with a protein called hamartin (encoded by the TSC1 gene). This hamartin-tuberin tumor suppressor complex plays a critical role in growth control as a negative regulator of the mammalian target of rapamycin (mTOR) pathway^{[145][146]}. Mutations in TSC1/TSC2 tumor suppressor genes that result in inactivation of the complex are commonly found in patients with tuberous sclerosis complex^{[147][148][149]}, while the loss of heterozygosity (LOH) in TSC1/TSC2 has been identified in head and neck squamous cell carcinoma (HNSCC)^[150] and endometrial cancer^[151]. TSC2 deletion, splicing-mutant, and inactivating mutations such as A1141T, G305V, S1514X, and R1032X, has been identified in TSC2-null hepatocellular carcinoma (HCC) cell lines, patient-derived xenograft, and primary tumors. Mutations in the TSC1 and TSC2 genes cause the autosomal dominant genetic disorder tuberous sclerosis complex (TSC)^[153].

Therapeutic and prognostic relevance

Genomic alterations with activating effects of the mTOR signaling pathway (including deletion/inactivation of TSC1/TSC2) have been shown to confer sensitivity to everolimus across multiple cancer types, such as bladder cancer, gastric cancer, sarcoma, thyroid cancer, hepatocellular carcinoma (HCC) as well as head and neck squamous cell carcinoma (HNSCC)^{[154][155][158]}. Results from one Phase II study of advanced endometrial cancer showed that mutations in AKT1, TSC1, and TSC2 might predict sensitivity to temsirolimus^[156]. Recent studies indicated that there are mTORC1-independent signaling pathways downstream of hamartin-tuberin, which may represent new therapeutic targets^[157].

Everolimus has been approval by the U.S. FDA for Tuberous Sclerosis Complex (TSC)-associated renal angiomyolipoma and Tuberous Sclerosis Complex (TSC)-associated subependymal giant cell astrocytoma (SEGA). This approval is based on the results from EXIST-1, EXIST-2, and Study 2485 trials (NCT00789828, NCT00790400, and NCT00411619).

TYMS Amplification

Biological Impact

TYMS (Thymidylate Synthetase) gene encodes the thymidylate synthase that catalyzes the methylation of deoxyuridylate to deoxythymidylate. The enzyme is critical for DNA replication and repair^{[159][160][161]}. TYMS polymorphisms may be associated with etiology of neoplasia, including acute lymphoblastic leukemia^[162], breast cancer, and response to chemotherapy^[163].

Therapeutic and prognostic relevance

Thymidylate synthase gene amplification was associated with pemetrexed resistance in patients with advanced non-small cell lung cancer^{[164][165][166][167]}, and 5-FU resistance in CRC patients^[168].

ACT Onco[®] + Report

US FDA-APPROVED DRUG(S)

Abemaciclib (VERZENIO)

Abemaciclib is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. Abemaciclib is developed and marketed by Eli Lilly under the trade name VERZENIO.

- FDA Approval Summary of Abemaciclib (VERZENIO)

monarchE NCT03155997	Breast cancer (Approved on 2021/10/12)
	HR-positive, HER2-negative
	Abemaciclib + tamoxifen/aromatase inhibitor vs. Tamoxifen/aromatase inhibitor [IDFS at 36 months(%): 86.1 vs. 79.0]
MONARCH 3 ^[169] NCT02246621	Breast cancer (Approved on 2018/02/26)
	HR-positive, HER2-negative
	Abemaciclib + anastrozole/letrozole vs. Placebo + anastrozole/letrozole [PFS(M): 28.2 vs. 14.8]
MONARCH 2 ^[97] NCT02107703	Breast cancer (Approved on 2017/09/28)
	HR-positive, HER2-negative
	Abemaciclib + fulvestrant vs. Placebo + fulvestrant [PFS(M): 16.4 vs. 9.3]
MONARCH 1 ^[170] NCT02102490	Breast cancer (Approved on 2017/09/28)
	HR-positive, HER2-negative
	Abemaciclib [ORR(%): 19.7 vs. 17.4]

Dasatinib (SPRYCEL)

Dasatinib is an oral Bcr-Abl tyrosine kinase inhibitor (inhibits the "Philadelphia chromosome") and Src family tyrosine kinase inhibitor. Dasatinib is produced by Bristol-Myers Squibb and sold under the trade name SPRYCEL.

- FDA Approval Summary of Dasatinib (SPRYCEL)

DASISION ^[171] NCT00481247	Chronic myeloid leukemia (Approved on 2010/10/28)
	-
	Dasatinib vs. Imatinib [ORR(%): 76.8 vs. 66.2]
^[172] NCT00123474	Chronic myeloid leukemia (Approved on 2007/11/08)
	-
	Dasatinib [ORR(%): 63.0]
^[173] NCT00123487	Acute lymphocytic leukemia (Approved on 2006/06/28)
	-
	Dasatinib [ORR(%): 38.0]

ACT Onco[®] + Report

Everolimus (AFINITOR)

Everolimus, a derivative of sirolimus, works as an inhibitor of mammalian target of rapamycin complex 1 (mTORC1) and blocks mTORC1-mediated downstream signals for cell growth, proliferation, and survival. Everolimus is developed and marketed by Novartis under the trade name AFINITOR.

- FDA Approval Summary of Everolimus (AFINITOR)

RADIANT-4 ^[174] NCT01524783	Lung or gastrointestinal neuroendocrine tumor (Approved on 2016/02/26)
	- Everolimus vs. Placebo [PFS(M): 11 vs. 3.9]
BOLERO-2 ^[175] NCT00863655	Breast cancer (Approved on 2012/07/20)
	ER+/HER2- Everolimus + exemestane vs. Placebo + exemestane [PFS(M): 7.8 vs. 3.2]
EXIST-2 NCT00790400	Tuberous sclerosis complex (tsc)-associated renal angiomyolipoma (Approved on 2012/04/26)
	- Everolimus vs. Placebo [ORR(%): 41.8 vs. 0]
RADIANT-3 ^[176] NCT00510068	Pancreatic neuroendocrine tumor (Approved on 2011/05/05)
	- Everolimus vs. Placebo [PFS(M): 11 vs. 4.6]
EXIST-1 ^[177] NCT00789828	Subependymal giant cell astrocytoma (Approved on 2010/10/29)
	- Everolimus vs. Placebo [ORR(%): 35.0]
RECORD-1 ^[178] NCT00410124	Renal cell carcinoma (Approved on 2009/05/30)
	- Everolimus vs. Placebo [PFS(M): 4.9 vs. 1.9]

Niraparib (Zejula)

Niraparib is an oral, small molecule inhibitor of the DNA repair enzyme poly (ADP-ribose) polymerase-1 and -2 (PARP-1, -2). Niraparib is developed and marketed by Tesaro under the trade name ZEJULA.

- FDA Approval Summary of Niraparib (Zejula)

PRIMA NCT02655016	Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma (Approved on 2020/04/29)
	- Niraparib vs. Placebo [PFS (overall population)(M): 13.8 vs. 8.2]
QUADRA ^[179] NCT02354586	Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma (Approved on 2019/10/23)
	HRD-positive (defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability) Niraparib [ORR(%): 24.0, DOR(M): 8.3]
NOVA ^[180] NCT01847274	Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma (Approved on 2017/03/27)
	- Niraparib vs. Placebo [PFS (overall population)(M): 11.3 vs. 4.7]

ACT Onco® + Report

Olaparib (LYNPARZA)

Olaparib is an oral, small molecule inhibitor of poly (ADP-ribose) polymerase-1, -2, and -3 (PARP-1, -2, -3). Olaparib is developed by KuDOS Pharmaceuticals and marketed by AstraZeneca under the trade name LYNPARZA.

- FDA Approval Summary of Olaparib (LYNPARZA)

OlympiA NCT02032823	Her2-negative high-risk early breast cancer (Approved on 2022/03/11)
	gBRCA Olaparib vs. Placebo [invasive disease-free survival (IDFS)(M):]
PROfound ^[181] NCT02987543	Prostate cancer (Approved on 2020/05/19)
	ATMm, BRCA1m, BRCA2m, BARD1m, BRIP1m, CDK12m, CHEK1m, CHEK2m, FANCLm, PALB2m, RAD51Bm, RAD51Cm, RAD51Dm, RAD54Lm Olaparib vs. Enzalutamide or abiraterone acetate [PFS(M): 5.8 vs. 3.5]
PAOLA-1 ^[182] NCT02477644	Ovarian cancer (Approved on 2020/05/08)
	HRD-positive (defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability) Olaparib + bevacizumab vs. Placebo + bevacizumab [PFS(M): 37.2 vs. 17.7]
POLO ^[183] NCT02184195	Pancreatic adenocarcinoma (Approved on 2019/12/27)
	Germline BRCA mutation (deleterious/suspected deleterious) Olaparib vs. Placebo [ORR(%): 23.0 vs. 12.0, PFS(M): 7.4 vs. 3.8]
SOLO-1 ^[184] NCT01844986	Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma (Approved on 2018/12/19)
	Germline or somatic BRCA-mutated (gBRCAm or sBRCAm) Olaparib vs. Placebo [PFS(M): NR vs. 13.8]
OlympiAD ^[185] NCT02000622	Breast cancer (Approved on 2018/02/06)
	Germline BRCA mutation (deleterious/suspected deleterious) HER2-negative Olaparib vs. Chemotherapy [PFS(M): 7 vs. 4.2]
SOLO-2/ENGOT-Ov21 ^[186] NCT01874353	Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma (Approved on 2017/08/17)
	gBRCA+ Olaparib vs. Placebo [PFS(M): 19.1 vs. 5.5]
Study19 ^[187] NCT00753545	Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma (Approved on 2017/08/17)
	- Olaparib vs. Placebo [PFS(M): 8.4 vs. 4.8]
Study 42 ^[188] NCT01078662	Ovarian cancer (Approved on 2014/12/19)
	Germline BRCA mutation (deleterious/suspected deleterious) Olaparib [ORR(%): 34.0, DOR(M): 7.9]

ACT Onco[®] + Report

Palbociclib (IBRANCE)

Palbociclib is an oral, cyclin-dependent kinase (CDK) inhibitor specifically targeting CDK4 and CDK6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Palbociclib is developed and marketed by Pfizer under the trade name IBRANCE.

- FDA Approval Summary of Palbociclib (IBRANCE)

PALOMA-2 ^[189] NCT01740427	Breast cancer (Approved on 2017/03/31)
	ER+, HER2-
	Palbociclib + letrozole vs. Placebo + letrozole [PFS(M): 24.8 vs. 14.5]
PALOMA-3 ^[190] NCT01942135	Breast cancer (Approved on 2016/02/19)
	ER+, HER2-
	Palbociclib + fulvestrant vs. Placebo + fulvestrant [PFS(M): 9.5 vs. 4.6]

Ribociclib (KISQALI)

Ribociclib is a cyclin-dependent kinase (CDK) inhibitor specifically targeting cyclin D1/CDK4 and cyclin D3/CDK6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Ribociclib is developed by Novartis and Astex Pharmaceuticals and marketed by Novartis under the trade name KISQALI.

- FDA Approval Summary of Ribociclib (KISQALI)

MONALEESA-2 ^[96] NCT01958021	Breast cancer (Approved on 2017/03/13)
	HR+, HER2-
	Ribociclib vs. Letrozole [PFS(M): NR vs. 14.7]

Rucaparib (RUBRACA)

Rucaparib is an inhibitor of the DNA repair enzyme poly (ADP-ribose) polymerase-1, -2 and -3 (PARP-1, -2, -3). Rucaparib is developed and marketed by Clovis Oncology under the trade name RUBRACA.

- FDA Approval Summary of Rucaparib (RUBRACA)

TRITON2 NCT02952534	Prostate cancer (Approved on 2020/05/15)
	gBRCA+, sBRCA
	Rucaparib [ORR(%): 44.0, DOR(M): NE]
ARIEL3 ^[191] NCT01968213	Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma (Approved on 2018/04/06)
	All HRD tBRCA
	Rucaparib vs. Placebo [PFS (All)(M): 10.8 vs. 5.4, PFS (HRD)(M): 13.6 vs. 5.4, PFS (tBRCA)(M): 16.6 vs. 5.4]
ARIEL2 ^[192] NCT01482715, NCT01891344	Ovarian cancer (Approved on 2016/12/19)
	Germline and/or somatic BRCA mutation
	Rucaparib [ORR(%): 54.0]

ACT Onco[®] + Report

Talazoparib (TALZENNA)

Talazoparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1 and PARP2. Talazoparib is developed and marketed by Pfizer under the trade name TALZENNA.

- FDA Approval Summary of Talazoparib (TALZENNA)

EMBRACA ^[193] NCT01945775	Breast cancer (Approved on 2018/10/16)
	Germline BRCA mutation (deleterious/suspected deleterious) HER2-negative
	Talazoparib vs. Chemotherapy [PFS(M): 8.6 vs. 5.6]

Temsirolimus (TORISEL)

Temsirolimus is a soluble ester of sirolimus (rapamycin, brand-name drug Rapamune) and functions as an inhibitor of mammalian target of rapamycin complex (mTORC). The inhibitory molecular mechanism is similar to Everolimus. Temsirolimus is developed by Wyeth Pharmaceuticals and marketed by Pfizer under the trade name TORISEL.

- FDA Approval Summary of Temsirolimus (TORISEL)

[194] NCT00065468	Renal cell carcinoma (Approved on 2007/05/30)
	-
	Temsirolimus vs. Ifn-α [OS(M): 10.9 vs. 7.3]

D=day; W=week; M=month

ACT Onco[®] + Report

ONGOING CLINICAL TRIALS

Trials were searched by applying filters: study status, patient's diagnosis, intervention, location and/or biomarker(s). Please visit <https://clinicaltrials.gov> to search and view for a complete list of open available and updated matched trials.

No trial has been found.

ACT Onco[®] + Report


SUPPLEMENTARY INFORMATION OF TESTING RESULTS DETAILED INFORMATION OF VARIANTS WITH CLINICAL RELEVANCE

- Single Nucleotide and Small InDel Variants

Gene	Amino Acid Change	Exon	cDNA Change	Accession Number	COSMIC ID	Allele Frequency	Coverage
KRAS	G12R	2	c.34G>C	NM_004985	COSM518	46.9%	3130
TP53	S127F	5	c.380C>T	NM_000546	COSM44226	34.3%	542

- Copy Number Alterations

Observed copy number (CN) for each evaluated position is shown on the y-axis. Regions referred to as amplification or deletion are shown in color. Regions without significant changes are represented in gray.



ACT Onco[®] + Report

OTHER DETECTED VARIANTS

Gene	Amino Acid Change	Exon	cDNA Change	Accession Number	COSMIC ID	Allele Frequency	Coverage
CDKN1A	Splice region	2	c.-3G>A	NM_000389	COSM3076223	51.5%	1008
KDM6A	T584M	16	c.1751C>T	NM_021140	COSM9213526	41.1%	2455
KMT2A	S2806L	27	c.8417C>T	NM_001197104	-	11.4%	709
PGF	D165N	7	c.493G>A	NM_002632	COSM2138332	46.3%	986
RET	V292M	5	c.874G>A	NM_020975	COSM6381457	48.6%	247
SMARCA4	P222L	5	c.665C>T	NM_001128844	-	50.3%	821
SMO	T179M	2	c.536C>T	NM_005631	COSM6927006	50.7%	533
TSHR	K700E	10	c.2098A>G	NM_000369	-	43.1%	1325


Note:

- This table enlists variants detected by the panel other than those with clinical relevance (reported in Testing Result section). The clinical impact of a genetic variant is determined according to ACT Genomics in-house clinical knowledge database. A negative result does not necessarily indicate absence of biological effect on the tumor. Some variants listed here may possibly have preclinical data or may show potential clinical relevance in the future.

ACT Onco[®] + Report

TEST DETAILS

SPECIMEN RECEIVED AND PATHOLOGY REVIEW



- Collection date: May 2022
- Facility retrieved: 臺北榮總
- H&E-stained section No.: S11170683A
- Collection site: Pancreas
- Examined by: Dr. Chien-Ta Chiang
 1. The percentage of viable tumor cells in total cells in the whole slide (%): 10%
 2. The percentage of viable tumor cells in total cells in the encircled areas in the whole slide (%): 30%
 3. The percentage of necrotic cells (including necrotic tumor cells) in total cells in the whole slide (%): 0%
 4. The percentage of necrotic cells (including necrotic tumor cells) in total cells in the encircled areas in the whole slide (%): 0%
 5. Additional comment: NA
- Manual macrodissection: Performed on the highlighted region
- The outline highlights the area of malignant neoplasm annotated by a pathologist.

RUN QC

- Panel: ACTOnco[®]+

DNA test

- Mean Depth: 896x
- Target Base Coverage at 100x: 94%

RNA test

- Average unique RNA Start Sites per control GSP2: 23

ACT Onco[®] + Report

LIMITATIONS

1. This test does not provide information of variant causality and does not detect variants in non-coding regions that could affect gene expression. This report does not report polymorphisms and we do not classify whether a mutation is germline or somatic. Variants identified by this assay were not subject to validation by Sanger or other technologies.
2. The possibility cannot be excluded that certain pathogenic variants detected by other sequencing tools may not be reported in the test because of technical limitation of bioinformatics algorithm or the NGS sequencing platform, e.g. low coverage.
3. This test has been designed to detect fusions in 13 genes sequenced. Therefore, fusion in genes not covered by this test would not be reported. For novel fusions detected in this test, Sanger sequencing confirmation is recommended if residue specimen is available.

NEXT-GENERATION SEQUENCING (NGS) METHODS

DNA test

Extracted genomic DNA was amplified using primers targeting coding exons of analyzed genes and subjected to library construction. Barcoded libraries were subsequently conjugated with sequencing beads by emulsion PCR and enriched using Ion Chef system. Sequencing was performed according to Ion Proton or Ion S5 sequencer protocol (Thermo Fisher Scientific).

Raw reads generated by the sequencer were mapped to the hg19 reference genome using the Ion Torrent Suite. Coverage depth was calculated using Torrent Coverage Analysis plug-in. Single nucleotide variants (SNVs) and short insertions/deletions (InDels) were identified using the Torrent Variant Caller plug-in. VEP (Variant Effect Predictor) was used to annotate every variant using databases from Clinvar, COSMIC and Genome Aggregation database. Variants with coverage ≥ 25 , allele frequency $\geq 5\%$ and actionable variants with allele frequency $\geq 2\%$ were retained. This test provides uniform coverage of the targeted regions, enabling target base coverage at $100\times \geq 85\%$ with a mean coverage $\geq 500\times$.

Variants reported in Genome Aggregation database with $> 1\%$ minor allele frequency (MAF) were considered as polymorphisms. ACT Genomics in-house database was used to determine technical errors. Clinically actionable and biologically significant variants were determined based on the published medical literature.

The copy number alterations (CNAs) were predicted as described below:

Amplicons with read counts in the lowest 5th percentile of all detectable amplicons and amplicons with a coefficient of variation ≥ 0.3 were removed. The remaining amplicons were normalized to correct the pool design bias. ONCOCNV (an established method for calculating copy number aberrations in amplicon sequencing data by Boeva et al., 2014) was applied for the normalization of total amplicon number, amplicon GC content, amplicon length, and technology-related biases, followed by segmenting the sample with a gene-aware model. The method was used as well for establishing the baseline of copy number variations.

Tumor mutational burden (TMB) was calculated by using the sequenced regions of ACTOnco[®]+ to estimate the number of somatic nonsynonymous mutations per megabase of all protein-coding genes (whole exome). The TMB calculation predicted somatic variants and applied a machine learning model with a cancer hotspot correction. TMB may be reported as "TMB-High", "TMB-Low" or "Cannot Be Determined". TMB-High corresponds to ≥ 7.5 mutations per megabase (Muts/Mb); TMB-Low corresponds to < 7.5 Muts/Mb. TMB is reported as "Cannot Be Determined" if the tumor purity of the sample is $< 30\%$.

Classification of microsatellite instability (MSI) status is determined by a machine learning prediction algorithm. The change of a number of repeats of different lengths from a pooled microsatellite stable (MSS) baseline in > 400 genomic loci are used as the features for the algorithm. The final output of the results is either microsatellite Stable (MSS) or microsatellite instability high (MSI-H).

RNA test

Extracted RNA was reverse-transcribed and subjected to library construction. Sequencing was performed according to Ion Proton or Ion S5 sequencer protocol (Thermo Fisher Scientific). To ensure sequencing quality for fusion variant analysis, the average unique RNA Start Sites (SS) per control Gene Specific Primer 2 (GSP 2) should be ≥ 10 .

ACT Onco[®] + Report

The fusion analysis pipeline aligned sequenced reads to the human reference genome, identified regions that map to noncontiguous regions of the genome, applied filters to exclude probable false-positive events and, annotated previously characterized fusion events according to Quiver Gene Fusion Database, a curated database owned and maintained by ArcherDX. In general, samples with detectable fusions need to meet the following criteria: (1) Number of unique start sites (SS) for the GSP2 ≥ 3 ; (2) Number of supporting reads spanning the fusion junction ≥ 5 ; (3) Percentage of supporting reads spanning the fusion junction $\geq 10\%$; (4) Fusions annotated in Quiver Gene Fusion Database.

DATABASE USED

- Reference genome: Human genome sequence hg19
- COSMIC v.92
- Genome Aggregation database r2.1.1
- ClinVar (version 20210404)
- ACT Genomics in-house database
- Quiver Gene Fusion Database version 5.1.18

Variant Analysis:

醫檢師陳韻仔 博士
Yun-Yu Chen Ph.D.
檢字第 015647 號

Yun Yu Chen

Sign Off

醫檢師陳韻仔 博士
Yun-Yu Chen Ph.D.
檢字第 015647 號

Yun Yu Chen

ACT Onco[®] + Report

GENE LIST SNV & CNV

ABCB1*	ABCC2*	ABCG2*	ABL1	ABL2	ADAMTS1	ADAMTS13	ADAMTS15	ADAMTS16	ADAMTS18	ADAMTS6	ADAMTS9
ADAMTSL1	ADGRA2	ADH1C*	AKT1	AKT2	AKT3	ALDH1A1*	ALK	AMER1	APC	AR	ARAF
ARID1A	ARID1B	ARID2	ASXL1	ATM	ATR	ATRX	AURKA	AURKB	AXIN1	AXIN2	AXL
B2M	BAP1	BARD1	BCL10	BCL2*	BCL2L1	BCL2L2*	BCL6	BCL9	BCOR	BIRC2	BIRC3
BLM	BMPR1A	BRAF	BRCA1	BRCA2	BRD4	BRIP1	BTG1	BTG2*	BTB	BUB1B	CALR
CANX	CARD11	CASP8	CBFB	CBL	CCNA1	CCNA	CCNB1	CCNB2	CCNB3	CCND1	CCND2
CCND3	CCNE1	CCNE2	CCNH	CD19	CD274	CD58	CD70*	CD79A	CD79B	CDC73	CDH1
CDK1	CDK12	CDK2	CDK4	CDK5	CDK6	CDK7	CDK8	CDK9	CDKN1A	CDKN1B	CDKN2A
CDKN2B	CDKN2C	CEBPA*	CHEK1	CHEK2	CIC	CREBBP	CRKL	CRLF2	CSF1R	CTCF	CTLA4
CTNNA1	CTNNB1	CUL3	CYLD	CYP1A1*	CYP2B6*	CYP2C19*	CYP2C8*	CYP2D6	CYP2E1*	CYP3A4*	CYP3A5*
DAXX	DCUN1D1	DDR2	DICER1	DNMT3A	DOT1L	DPYD	DTX1	E2F3	EGFR	EP300	EPCAM
EPHA2	EPHA3	EPHA5	EPHA7	EPHB1	ERBB2	ERBB3	ERBB4	ERCC1	ERCC2	ERCC3	ERCC4
ERCC5	ERG	ESR1	ESR2	ETV1	ETV4	EZH2	FAM46C	FANCA	FANCC	FANCD2	FANCE
FANCF	FANCG	FANCL	FAS	FAT1	FBXW7	FCGR2B	FGF1*	FGF10	FGF14	FGF19*	FGF23
FGF3	FGF4*	FGF6	FGFR1	FGFR2	FGFR3	FGFR4	FH	FLCN	FLT1	FLT3	FLT4
FOXL2*	FOXP1	FRG1	FUBP1	GATA1	GATA2	GATA3	GNA11	GNA13	GNAQ	GNAS	GREM1
GRIN2A	GSK3B	GSTP1*	GSTT1*	HGF	HIF1A	HIST1H1C*	HIST1H1E*	HNF1A	HR	HRA5*	HSP90AA1
HSP90AB1	HSPA4	HSPA5	IDH1	IDH2	IFNL3*	IGF1	IGF1R	IGF2	IKBKB	IKBKE	IKZF1
IL6	IL7R	INPP4B	INSR	IRF4	IRS1	IRS2*	JAK1	JAK2	JAK3	JUN*	KAT6A
KDM5A	KDM5C	KDM6A	KDR	KEAP1	KIT	KMT2A	KMT2C	KMT2D	KRAS	LCK	LIG1
LIG3	LMO1	LRP1B	LYN	MALT1	MAP2K1	MAP2K2	MAP2K4	MAP3K1	MAP3K7	MAPK1	MAPK3
MAX	MCL1	MDM2	MDM4	MED12	MEF2B	MEN1	MET	MITF	MLH1	MPL	MRE11
MSH2	MSH6	MTHFR*	MTOR	MUC16	MUC4	MUC6	MUTYH	MYC	MYCL	MYCN	MYD88
NAT2*	NBN	NEFH	NF1	NF2	NFE2L2	NFKB1	NFKBIA	NKX2-1*	NOTCH1	NOTCH2	NOTCH3
NOTCH4	NPM1	NQO1*	NRAS	NSD1	NTRK1	NTRK2	NTRK3	PAK3	PALB2	PARP1	PAX5
PAX8	PBRM1	PDCD1	PDCD1LG2	PDGFRA	PDGFRB	PDIA3	PGF	PHOX2B*	PIK3C2B	PIK3C2G	PIK3C3
PIK3CA	PIK3CB	PIK3CD	PIK3CG	PIK3R1	PIK3R2	PIK3R3	PIM1	PMS1	PMS2	POLB	POLD1
POLE	PPARG	PPP2R1A	PRDM1	PRKAR1A	PRKCA	PRKCB	PRKCG	PRKCI	PRKCQ	PRKDC	PRKN
PSMB8	PSMB9	PSME1	PSME2	PSME3	PTCH1	PTEN	PTGS2	PTPN11	PTPRD	PTPRT	RAC1
RAD50	RAD51	RAD51B	RAD51C	RAD51D	RAD52	RAD54L	RAF1	RARA	RB1	RBM10	RECQL4
REL	RET	RHOA	RICTOR	RNF43	ROS1	RPPH1	RPTOR	RUNX1	RUNX1T1	RXRA	SDHA
SDHB	SDHC	SDHD	SERPINB3	SERPINB4	SETD2	SF3B1	SGK1	SH2D1A*	SLC19A1*	SLC22A2*	SLC18A1*
SLC18A1*	SMAD2	SMAD3	SMAD4	SMARCA4	SMARCB1	SMO	SOC1*	SOX2*	SOX9	SPEN	SPOP
SRC	STAG2	STAT3	STK11	SUFU	SYK	SYNE1	TAF1	TAP1	TAP2	TAPBP	TBX3
TEK	TERT	TET1	TET2	TGFB2	TMSB4X*	TNF	TNFAIP3	TNFRSF14	TNFSF11	TOP1	TP53
TPMT*	TSC1	TSC2	TSHR	TYMS	U2AF1	UBE2A*	UBE2K	UBR5	UGT1A1*	USH2A	VDR*
VEGFA	VEGFB	VHL	WT1	XIAP	XPO1	XRCC2	ZNF217				

*Analysis of copy number alterations NOT available.

FUSION

ALK	BRAF	EGFR	FGFR1	FGFR2	FGFR3	MET	NRG1	NTRK1	NTRK2	NTRK3	RET	ROS1
-----	------	------	-------	-------	-------	-----	------	-------	-------	-------	-----	------


ACT Onco[®] + Report

APPENDIX

POSSIBLE THERAPEUTIC IMPLICATIONS FOR HETEROZYGOUS DELETION


Gene	Therapies	Possible effect
<i>ARID1A</i>	Dasatinib, Niraparib, Olaparib, Rucaparib, Talazoparib	sensitive
<i>TSC1</i>	Everolimus, Temsirolimus	sensitive
<i>TSC2</i>	Everolimus, Temsirolimus	sensitive
<i>RAD51</i>	Niraparib, Olaparib, Rucaparib, Talazoparib	sensitive
<i>SMAD4</i>	Cetuximab	resistant

SIGNALING PATHWAYS AND MOLECULAR-TARGETED AGENTS




1: Everolimus, Temsirolimus

ACT Onco[®] + Report



1: Olaparib, Niraparib, Rucaparib, Talazoparib



1: Abemaciclib, Palbociclib, Ribociclib

ACT Onco[®] + Report

DISCLAIMER

法律聲明

本檢驗報告僅提供專業醫療參考，結果需經專業醫師解釋及判讀。基因突變資訊非必具備藥物或治療有效性指標，反之亦然。本檢驗報告提供之用藥指引不聲明或保證其臨床有效性，反之亦然。本基因檢測方法係由本公司研究開發，已經過有效性測試。

本檢驗報告非經本公司許可，不得私自變造、塗改，或以任何方式作為廣告及其他宣傳之用途。

本公司於提供檢驗報告後，即已完成本次契約義務，後續之報告解釋、判讀及用藥、治療，應自行尋求相關專業醫師協助，若需將報告移件其他醫師，本人應取得該醫師同意並填寫移件申請書，主動告知行動基因，行動基因僅能配合該醫師意願與時間提供醫師解說。

醫療決策需由醫師決定

任何治療與用藥需經由醫師在考慮病患所有健康狀況相關資訊包含健檢、其他檢測報告和病患意願後，依照該地區醫療照護標準由醫師獨立判斷。醫師不應僅依據單一報告結果(例如本檢測或本報告書內容)做決策。

基因突變與用藥資訊並非依照有效性排序

本報告中列出之生物標記變異與藥物資訊並非依照潛在治療有效性排序。

證據等級

藥物潛在臨床效益(或缺乏潛在臨床效益)的實證證據是依據至少一篇臨床療效個案報告或臨床前試驗做為評估。本公司盡力提供適時及準確之資料，但由於醫學科技之發展日新月異，本公司不就本報告提供的資料是否為準確、適宜或最新作保證。

責任

本檢驗報告僅提供專業醫療參考，本公司及其員工不對任何由使用本報告之內容引起的直接、間接、特殊、連帶或衍生的損失或損害承擔責任。

ACT Onco[®] + Report

REFERENCE

1. PMID: 2453289; 1988, Cell;53(4):549-54
Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes.
2. PMID: 2114981; 1990, Eur J Clin Invest;20(3):225-35
ras oncogenes: their role in neoplasia.
3. PMID: 20617134; 2010, J Biomed Biotechnol;2010():150960
Clinical relevance of KRAS in human cancers.
4. PMID: 21993244; 2011, Nat Rev Cancer;11(11):761-74
RAS oncogenes: weaving a tumorigenic web.
5. PMID: 3047672; 1988, Nucleic Acids Res;16(16):7773-82
KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas.
6. PMID: 3587348; 1987, Nature;327(6120):293-7
Prevalence of ras gene mutations in human colorectal cancers.
7. PMID: 1942608; 1991, Nihon Shokakibyo Gakkai Zasshi;88(8):1539-44
[Prevalence of K-ras gene mutations in human colorectal cancers].
8. PMID: 2252272; 1990, Am Rev Respir Dis;142(6 Pt 2):S27-30
The ras oncogenes in human lung cancer.
9. PMID: 1486840; 1992, Environ Health Perspect;98():13-24
Role of proto-oncogene activation in carcinogenesis.
10. PMID: 23455880; 2013, J Cancer Res Clin Oncol;139(6):953-61
KRAS allele-specific activity of sunitinib in an isogenic disease model of colorectal cancer.
11. PMID: 26037647; 2015, Mol Cancer Res;13(9):1325-35
Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations.
12. PMID: 25414119; 2014, Drugs;74(18):2111-28
The biology and clinical development of MEK inhibitors for cancer.
13. PMID: 25265492; 2014, N Engl J Med;371(20):1877-88
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
14. PMID: 22663011; 2012, N Engl J Med;367(2):107-14
Improved survival with MEK inhibition in BRAF-mutated melanoma.
15. PMID: 25265494; 2014, N Engl J Med;371(20):1867-76
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
16. PMID: 29573941; 2018, Lancet Oncol;19(5):603-615
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
17. PMID: 26075998; 2014, Gynecol Oncol Rep;10():28-9
Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation.
18. PMID: 29946554; 2018, Gynecol Oncol Rep;25():41-44
Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment.
19. PMID: 25722381; 2015, Ann Oncol;26(5):894-901
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-

ACT Onco[®] + Report

small-cell lung cancer (NSCLC)†.

20. PMID: 24947927; 2014, Clin Cancer Res;20(16):4251-61
Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.
21. PMID: 27340376; 2016, Curr Colorectal Cancer Rep;12():141-150
Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer.
22. PMID: 22392911; 2012, Clin Cancer Res;18(9):2515-25
Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.
23. PMID: 26369631; 2016, Clin Cancer Res;22(2):405-14
Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.
24. PMID: 25937522; 2015, Eur J Cancer;51(10):1243-52
FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer.
25. PMID: 19188670; 2009, J Clin Oncol;27(12):2091-6
American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.
26. PMID: 18802721; 2008, Virchows Arch;453(5):417-31
KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.
27. PMID: 25605843; 2015, J Clin Oncol;33(7):692-700
Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.
28. PMID: 27422777; 2016, Tumour Biol;37(9):11645-11655
Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer.
29. PMID: 24024839; 2013, N Engl J Med;369(11):1023-34
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
30. PMID: 24666267; 2014, Acta Oncol;53(7):852-64
The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
31. PMID: 27722750; 2017, JAMA Oncol;3(2):194-201
Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials.
32. PMID: 27736842; 2016, Br J Cancer;115(10):1206-1214
A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer.
33. PMID: 20921465; 2010, J Clin Oncol;28(31):4697-705
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
34. PMID: 24407191; 2014, Br J Cancer;110(5):1148-54
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.
35. PMID: 23224737; 2013, Clin Cancer Res;19(3):743-51
A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIB or IV) non-small cell lung cancer with a KRAS mutation.
36. PMID: 26307133; 2016, Clin Cancer Res;22(2):374-82

ACT Onco[®] + Report

Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.

37. PMID: 23828442; 2013, Med Oncol;30(3):650
KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials.
38. PMID: 28632865; 2017, JAMA;317(23):2392-2401
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
39. PMID: 18349398; 2008, J Clin Oncol;26(9):1472-8
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
40. PMID: 23401440; 2013, J Clin Oncol;31(8):1112-21
KRAS mutation: should we test for it, and does it matter?
41. PMID: 18024870; 2007, J Clin Oncol;25(33):5240-7
Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer.
42. PMID: 15923428; 2005, Ann Oncol;16 Suppl 4():iv44-49
Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies.
43. PMID: 26484411; 2015, Br J Cancer;113(9):1254-8
Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum.
44. PMID: 24549645; 2013, J Pathol;231(4):449-56
KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.
45. PMID: 22983505; 2013, J Gastroenterol;48(5):640-6
Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer.
46. PMID: 30867592; 2019, Nature;567(7749):521-524
Efficacy of MEK inhibition in patients with histiocytic neoplasms.
47. PMID: 34901697; 2021, J Pancreat Cancer;7(1):65-70
Cobimetinib Plus Gemcitabine: An Active Combination in KRAS G12R-Mutated Pancreatic Ductal Adenocarcinoma Patients in Previously Treated and Failed Multiple Chemotherapies.
48. PMID: 24739573; 2014, Nat Rev Cancer;14(5):359-70
Unravelling mechanisms of p53-mediated tumour suppression.
49. PMID: 21125671; 2011, J Pathol;223(2):137-46
Haplo-insufficiency: a driving force in cancer.
50. PMID: 22866089; 2011, Oncol Lett;2(2):363-369
TP53 genetic alterations in Arab breast cancer patients: Novel mutations, pattern and distribution.
51. PMID: 26718964; 2016, Oncol Rep;35(3):1859-67
Complex analysis of the p53 tumor suppressor in lung carcinoma.
52. PMID: 27998224; 2016, J Clin Oncol;34(36):4354-4361
Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.
53. PMID: 26646755; 2016, Ann Oncol;27(3):539-43
TP53 mutational status is predictive of pazopanib response in advanced sarcomas.
54. PMID: 25669829; 2015, Ann Oncol;26(5):1012-8
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant

ACT Onco[®] + Report

p53 degradation.

55. PMID: 27466356; 2016, Mol Cancer Ther;15(10):2475-2485
TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics.
56. PMID: 23670029; 2013, Oncotarget;4(5):705-14
P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy.
57. PMID: 17145525; 2006, Semin Oncol;33(5 Suppl 10):S8-14
Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.
58. PMID: 21399868; 2011, Int J Oncol;38(5):1445-52
p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer.
59. PMID: 20549698; 2011, Int J Cancer;128(8):1813-21
p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines.
60. PMID: 10786679; 2000, Cancer Res;60(8):2155-62
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
61. PMID: 25672981; 2015, Cancer Res;75(7):1187-90
VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy.
62. PMID: 10757798; 2000, Mol Cell Biol;20(9):3137-46
The human SWI-SNF complex protein p270 is an ARID family member with non-sequence-specific DNA binding activity.
63. PMID: 25387058; 2015, Annu Rev Pathol;10():145-71
SWI/SNF chromatin remodeling and human malignancies.
64. PMID: 23208470; 2013, Cancer Discov;3(1):35-43
ARID1A mutations in cancer: another epigenetic tumor suppressor?
65. PMID: 20826764; 2010, Science;330(6001):228-31
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.
66. PMID: 20942669; 2010, N Engl J Med;363(16):1532-43
ARID1A mutations in endometriosis-associated ovarian carcinomas.
67. PMID: 21590771; 2011, J Pathol;224(3):328-33
Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas.
68. PMID: 21412130; 2011, Am J Surg Pathol;35(5):625-32
Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma.
69. PMID: 22037554; 2011, Nat Genet;43(12):1219-23
Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer.
70. PMID: 26125128; 2015, Expert Opin Ther Targets;19(11):1419-22
Potential therapeutic targets in ARID1A-mutated cancers.
71. PMID: 29093822; 2017, Gynecol Oncol Res Pract;4():17
EZH2 inhibition in ARID1A mutated clear cell and endometrioid ovarian and endometrioid endometrial cancers.
72. PMID: 24979463; 2014, Oncotarget;5(14):5295-303
Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition.
73. PMID: 27364904; 2016, Mol Cancer Ther;15(7):1472-84
Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib.

ACT Onco[®] + Report

74. PMID: 27172896; 2016, Clin Cancer Res;22(21):5238-5248
Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance.
75. PMID: 22101352; 2012, Mod Pathol;25(2):282-8
Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma.
76. PMID: 24459582; 2014, J Gynecol Oncol;25(1):58-63
Decreased ARID1A expression is correlated with chemoresistance in epithelial ovarian cancer.
77. PMID: 26770240; 2015, J Breast Cancer;18(4):339-46
Loss of Tumor Suppressor ARID1A Protein Expression Correlates with Poor Prognosis in Patients with Primary Breast Cancer.
78. PMID: 21889920; 2012, Cancer Epidemiol;36(3):288-93
Frequent low expression of chromatin remodeling gene ARID1A in breast cancer and its clinical significance.
79. PMID: 25311944; 2014, Hum Pathol;45(12):2430-6
Immunohistochemical detection of ARID1A in colorectal carcinoma: loss of staining is associated with sporadic microsatellite unstable tumors with medullary histology and high TNM stage.
80. PMID: 25561809; 2014, World J Gastroenterol;20(48):18404-12
Clinicopathologic and prognostic relevance of ARID1A protein loss in colorectal cancer.
81. PMID: 26069190; 2015, Cancer Discov;5(7):752-67
ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.
82. PMID: 17055429; 2006, Cell;127(2):265-75
The regulation of INK4/ARF in cancer and aging.
83. PMID: 8521522; 1995, Cell;83(6):993-1000
Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest.
84. PMID: 9529249; 1998, Cell;92(6):725-34
ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways.
85. PMID: 16115911; 2005, Clin Cancer Res;11(16):5740-7
Comprehensive analysis of CDKN2A status in microdissected urothelial cell carcinoma reveals potential haploinsufficiency, a high frequency of homozygous co-deletion and associations with clinical phenotype.
86. PMID: 7550353; 1995, Nat Genet;11(2):210-2
Frequency of homozygous deletion at p16/CDKN2 in primary human tumours.
87. PMID: 24089445; 2013, Clin Cancer Res;19(19):5320-8
The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma.
88. PMID: 27849562; 2017, Gut;66(7):1286-1296
Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.
89. PMID: 25524798; 2015, Lancet Oncol;16(1):25-35
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
90. PMID: 28283584; 2017, Oncologist;22(4):416-421
Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration.
91. PMID: 27217383; 2016, Cancer Discov;6(7):740-53
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
92. PMID: 26715889; 2015, Curr Oncol;22(6):e498-501
Does CDKN2A loss predict palbociclib benefit?

ACT Onco[®] + Report

93. PMID: 25501126; 2015, Clin Cancer Res;21(5):995-1001
CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.
94. PMID: 27542767; 2016, Clin Cancer Res;22(23):5696-5705
A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas.
95. PMID: 24797823; 2014, Oncologist;19(6):616-22
Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel.
96. PMID: 27717303; 2016, N Engl J Med;375(18):1738-1748
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
97. PMID: 28580882; 2017, J Clin Oncol;35(25):2875-2884
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
98. PMID: 26728409; 2016, Clin Cancer Res;22(1):122-33
Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.
99. PMID: 31401335; 2019, Transl Oncol;12(11):1425-1431
Concomitant Genetic Alterations are Associated with Worse Clinical Outcome in EGFR Mutant NSCLC Patients Treated with Tyrosine Kinase Inhibitors.
100. PMID: 20930833; 2010, Nature;467(7316):667-8
DNA repair: A protein giant in its entirety.
101. PMID: 20729858; 2010, Nat Struct Mol Biol;17(10):1263-5
The breast cancer tumor suppressor BRCA2 promotes the specific targeting of RAD51 to single-stranded DNA.
102. PMID: 20729832; 2010, Nature;467(7316):678-83
Purified human BRCA2 stimulates RAD51-mediated recombination.
103. PMID: 22305526; 2012, Am J Hum Genet;90(2):301-7
RAD51 haploinsufficiency causes congenital mirror movements in humans.
104. PMID: 18243065; 2008, DNA Repair (Amst);7(5):686-93
The consequences of Rad51 overexpression for normal and tumor cells.
105. PMID: 24811120; 2014, Oncotarget;5(10):3261-72
Rad51 supports triple negative breast cancer metastasis.
106. PMID: 26317153; 2015, Cell Cycle;14(19):3190-202
High levels of RAD51 perturb DNA replication elongation and cause unscheduled origin firing due to impaired CHK1 activation.
107. PMID: 21807066; 2011, Biochim Biophys Acta;1816(2):209-18
RAD51 as a potential biomarker and therapeutic target for pancreatic cancer.
108. PMID: 10851081; 2000, Oncogene;19(23):2791-5
DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma.
109. PMID: 24741789; 2014, Rev Med Chir Soc Med Nat Iasi;118(1):133-40
Rad51 overexpression and resistance to genotoxic agents. A study in the fission yeast Schizosaccharomyces pombe.
110. PMID: 18618591; 2009, Mol Carcinog;48(2):105-9
Rad51 overexpression rescues radiation resistance in BRCA2-defective cancer cells.
111. PMID: 10807537; 2000, J Hum Genet;45(3):133-7
Identification of Rad51 alteration in patients with bilateral breast cancer.

ACT Onco[®] + Report

112. PMID: 26108708; 2015, Sci Rep;5():11588
RAD51 135G>C substitution increases breast cancer risk in an ethnic-specific manner: a meta-analysis on 21,236 cases and 19,407 controls.
113. PMID: 11248061; 2001, Proc Natl Acad Sci U S A;98(6):3232-6
A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers.
114. PMID: 17999359; 2007, Am J Hum Genet;81(6):1186-200
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies.
115. PMID: 30353044; 2018, Br J Cancer;119(11):1401-1409
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
116. PMID: 24577941; 2014, Mol Cancer Ther;13(5):1170-80
The use of Olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks.
117. PMID: 28759753; 2017, Biomed Pharmacother;94():165-168
Inhibition of Rad51 sensitizes breast cancer cells with wild-type PTEN to olaparib.
118. PMID: 25935112; 2015, Trends Biochem Sci;40(6):296-308
Structural determinants of Smad function in TGF- β signaling.
119. PMID: 19014666; 2008, Pathogenetics;1(1):2
Smad4 haploinsufficiency: a matter of dosage.
120. PMID: 9545410; 1998, Am J Hum Genet;62(5):1129-36
A gene for familial juvenile polyposis maps to chromosome 18q21.1.
121. PMID: 8553070; 1996, Science;271(5247):350-3
DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1.
122. PMID: 8673134; 1996, Nat Genet;13(3):343-6
Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers.
123. PMID: 18662538; 2008, Cell;134(2):215-30
TGFbeta in Cancer.
124. PMID: 9135016; 1997, Cancer Res;57(9):1731-4
Tumor-suppressive pathways in pancreatic carcinoma.
125. PMID: 23139211; 2013, Cancer Res;73(2):725-35
SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer.
126. PMID: 22810696; 2012, Nature;487(7407):330-7
Comprehensive molecular characterization of human colon and rectal cancer.
127. PMID: 25890228; 2015, World J Surg Oncol;13():128
Clinical outcome and expression of mutant P53, P16, and Smad4 in lung adenocarcinoma: a prospective study.
128. PMID: 19841540; 2009, J Clin Invest;119(11):3208-11
Smad4: gatekeeper gene in head and neck squamous cell carcinoma.
129. PMID: 15867212; 2005, Clin Cancer Res;11(9):3191-7
Differences in Smad4 expression in human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck squamous cell carcinoma.
130. PMID: 25589618; 2015, Clin Cancer Res;21(6):1447-56
Genomic analysis of metastatic cutaneous squamous cell carcinoma.

ACT Onco[®] + Report

131. PMID: 29703253; 2018, BMC Cancer;18(1):479
SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients.
132. PMID: 28522603; 2017, Clin Cancer Res;23(17):5162-5175
SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells.
133. PMID: 16144935; 2005, Clin Cancer Res;11(17):6311-6
SMAD4 levels and response to 5-fluorouracil in colorectal cancer.
134. PMID: 24384683; 2014, Br J Cancer;110(4):946-57
Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway.
135. PMID: 12237773; 2002, Br J Cancer;87(6):630-4
SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer.
136. PMID: 25749173; 2015, Transl Oncol;8(1):18-24
A Meta-Analysis of SMAD4 Immunohistochemistry as a Prognostic Marker in Colorectal Cancer.
137. PMID: 19478385; 2009, Cell Oncol;31(3):169-78
Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients.
138. PMID: 25681512; 2015, J Clin Pathol;68(5):341-5
Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer.
139. PMID: 26861460; 2016, Clin Cancer Res;22(12):3037-47
Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer.
140. PMID: 26947875; 2016, Transl Oncol;9(1):1-7
Prognostic Value of SMAD4 in Pancreatic Cancer: A Meta-Analysis.
141. PMID: 25760429; 2015, Pancreas;44(4):660-4
SMAD4 expression predicts local spread and treatment failure in resected pancreatic cancer.
142. PMID: 22504380; 2012, Pancreas;41(4):541-6
SMAD4 genetic alterations predict a worse prognosis in patients with pancreatic ductal adenocarcinoma.
143. PMID: 19584151; 2009, Clin Cancer Res;15(14):4674-9
SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.
144. PMID: 18425078; 2008, Mod Pathol;21(7):866-75
Expression of Smad2 and Smad4 in cervical cancer: absent nuclear Smad4 expression correlates with poor survival.
145. PMID: 21157483; 2011, Nat Rev Mol Cell Biol;12(1):21-35
mTOR: from growth signal integration to cancer, diabetes and ageing.
146. PMID: 12271141; 2002, Proc Natl Acad Sci U S A;99(21):13571-6
Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.
147. PMID: 9242607; 1997, Science;277(5327):805-8
Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34.
148. PMID: 8269512; 1993, Cell;75(7):1305-15
Identification and characterization of the tuberous sclerosis gene on chromosome 16.
149. PMID: 1303246; 1992, Nat Genet;2(1):37-41
Linkage of an important gene locus for tuberous sclerosis to a chromosome 16 marker for polycystic kidney disease.
150. PMID: 18538015; 2008, BMC Cancer;8(1):163

ACT Onco[®] + Report

Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma.

151. PMID: 28339086; 2017, Int J Oncol;50(5):1778-1784
Identification of novel mutations in endometrial cancer patients by whole-exome sequencing.
152. PMID: 20610279; 2010, Urol Oncol;28(4):409-28
Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium.
153. PMID: 17005952; 2006, N Engl J Med;355(13):1345-56
The tuberous sclerosis complex.
154. PMID: 22923433; 2012, Science;338(6104):221
Genome sequencing identifies a basis for everolimus sensitivity.
155. PMID: 26859683; 2016, Oncotarget;7(9):10547-56
Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.
156. PMID: 27016228; 2016, Gynecol Oncol;141(1):43-8
Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.
157. PMID: 26412398; 2015, Sci Rep;5():14534
PAK2 is an effector of TSC1/2 signaling independent of mTOR and a potential therapeutic target for Tuberous Sclerosis Complex.
158. PMID: 25724664; 2015, Mol Cancer Ther;14(5):1224-35
Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus.
159. PMID: 11502877; 2001, Mol Pharmacol;60(3):474-9
Inhibition of thymidylate synthase activity by antisense oligodeoxynucleotide and possible role in thymineless treatment.
160. PMID: 10482907; 1999, Br J Pharmacol;127(8):1777-86
Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells.
161. PMID: 16818500; 2006, Mol Cancer Ther;5(6):1423-33
Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesothelioma.
162. PMID: 29500934; 2018, J Clin Pharm Ther;43(4):507-512
Genotype and allele frequencies of TYMS rs2790 A > G polymorphism in a Chinese paediatric population with acute lymphoblastic leukaemia.
163. PMID: 28899623; 2018, Clin Breast Cancer;18(3):e301-e304
TYMS Gene Polymorphisms in Breast Cancer Patients Receiving 5-Fluorouracil-Based Chemotherapy.
164. PMID: 26220094; 2016, Clin Transl Oncol;18(1):107-12
Thymidylate synthase gene amplification predicts pemetrexed resistance in patients with advanced non-small cell lung cancer.
165. PMID: 21487406; 2011, Br J Cancer;104(10):1594-601
Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer.
166. PMID: 26502926; 2015, BMC Pulm Med;15():132
Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer.
167. PMID: 23242435; 2013, J Thorac Oncol;8(1):19-30
Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed.
168. PMID: 20727737; 2010, Eur J Cancer;46(18):3358-64
Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy.
169. PMID: 28968163; 2017, J Clin Oncol;35(32):3638-3646

ACT Onco[®] + Report

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.

170. PMID: 28533223; 2017, Clin Cancer Res;23(17):5218-5224
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2-Metastatic Breast Cancer.
171. PMID: 20525995; 2010, N Engl J Med;362(24):2260-70
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
172. PMID: 18541900; 2008, J Clin Oncol;26(19):3204-12
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.
173. PMID: 17496201; 2007, Blood;110(7):2309-15
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.
174. PMID: 26703889; 2016, Lancet;387(10022):968-977
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.
175. PMID: 22149876; 2012, N Engl J Med;366(6):520-9
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
176. PMID: 21306238; 2011, N Engl J Med;364(6):514-23
Everolimus for advanced pancreatic neuroendocrine tumors.
177. PMID: 23158522; 2013, Lancet;381(9861):125-32
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
178. PMID: 18653228; 2008, Lancet;372(9637):449-56
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
179. PMID: 30948273; 2019, Lancet Oncol;20(5):636-648
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
180. PMID: 27717299; 2016, N Engl J Med;375(22):2154-2164
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
181. PMID: 32343890; 2020, N Engl J Med;382(22):2091-2102
Olaparib for Metastatic Castration-Resistant Prostate Cancer.
182. PMID: 31851799; 2019, N Engl J Med;381(25):2416-2428
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
183. PMID: 31157963; 2019, N Engl J Med;381(4):317-327
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
184. PMID: 30345884; 2018, N Engl J Med;379(26):2495-2505
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
185. PMID: 28578601; 2017, N Engl J Med;377(6):523-533
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
186. PMID: 28754483; 2017, Lancet Oncol;18(9):1274-1284
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
187. PMID: 27617661; 2016, Lancet Oncol;17(11):1579-1589

ACT Onco[®] + Report

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.

188. PMID: 25366685; 2015, J Clin Oncol;33(3):244-50
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
189. PMID: 27959613; 2016, N Engl J Med;375(20):1925-1936
Palbociclib and Letrozole in Advanced Breast Cancer.
190. PMID: 26030518; 2015, N Engl J Med;373(3):209-19
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
191. PMID: 28916367; 2017, Lancet;390(10106):1949-1961
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
192. PMID: 27908594; 2017, Lancet Oncol;18(1):75-87
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
193. PMID: 30110579; 2018, N Engl J Med;379(8):753-763
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
194. PMID: 17538086; 2007, N Engl J Med;356(22):2271-81
Temsilolimus, interferon alfa, or both for advanced renal-cell carcinoma.